SciVision Biotech Inc.(TW:1786)
NT$52.00+0.90 (+10.52%)
TW:1786
SciVision Biotech Inc. financials statements
NT$52.00
At close:+0.90 (+10.52%)
SciVision Biotech Inc. (1786) Ratios
SciVision Biotech Inc. Ratios
TW:1786's free cash flow for Q2 2026 was NT$63.33M. For the 2026 fiscal year, TW:1786's free cash flow was decreased by NT$-4.56M and operating cash flow was NT$67.89M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 8.17 | 3.46 | 6.92 | 6.88 | 2.17 |
| Quick Ratio | 7.70 | 3.25 | 6.32 | 6.13 | 1.98 |
| Cash Ratio | 4.84 | 2.09 | 3.53 | 4.58 | 1.55 |
| Solvency Ratio | 0.35 | 0.67 | 0.45 | 0.35 | 0.19 |
| Operating Cash Flow Ratio | 0.71 | 0.80 | 1.88 | 1.39 | 0.23 |
| Short-Term Operating Cash Flow Coverage | 245.04 | 2.00 | 0.00 | 43.86 | 0.32 |
| Net Current Asset Value | NT$ 737.82M | NT$ 708.99M | NT$ 470.24M | NT$ 293.73M | NT$ 113.18M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.18 | 0.10 | 0.16 | 0.20 | 0.28 |
| Debt-to-Equity Ratio | 0.24 | 0.12 | 0.21 | 0.28 | 0.44 |
| Debt-to-Capital Ratio | 0.20 | 0.11 | 0.18 | 0.22 | 0.30 |
| Long-Term Debt-to-Capital Ratio | 0.16 | 0.00 | 0.17 | 0.20 | 0.17 |
| Financial Leverage Ratio | 1.35 | 1.24 | 1.33 | 1.39 | 1.56 |
| Debt Service Coverage Ratio | 29.84 | 2.23 | 30.32 | 19.62 | 0.52 |
| Interest Coverage Ratio | 24.37 | 43.74 | 24.29 | 27.29 | 15.40 |
| Debt to Market Cap | 0.07 | 0.02 | 0.06 | 0.11 | 0.18 |
| Interest Debt Per Share | 6.80 | 3.33 | 5.32 | 6.38 | 9.72 |
| Net Debt to EBITDA | -1.33 | -1.33 | -0.58 | -0.72 | -0.13 |
| Profitability Margins | |||||
| Gross Profit Margin | 72.00% | 74.23% | 71.88% | 66.72% | 67.62% |
| EBIT Margin | 21.42% | 33.65% | 30.61% | 32.30% | 24.55% |
| EBITDA Margin | 30.49% | 41.04% | 39.46% | 42.75% | 35.07% |
| Operating Profit Margin | 21.42% | 28.09% | 28.00% | 31.62% | 24.58% |
| Pretax Profit Margin | 20.87% | 33.01% | 29.45% | 31.14% | 22.96% |
| Net Profit Margin | 18.31% | 27.43% | 24.95% | 25.43% | 20.12% |
| Continuous Operations Profit Margin | 18.31% | 27.43% | 24.95% | 25.43% | 20.12% |
| Net Income Per EBT | 87.73% | 83.08% | 84.72% | 81.66% | 87.65% |
| EBT Per EBIT | 97.43% | 117.53% | 105.19% | 98.48% | 93.41% |
| Return on Assets (ROA) | 6.08% | 10.29% | 8.24% | 6.75% | 4.50% |
| Return on Equity (ROE) | 8.20% | 12.77% | 10.94% | 9.38% | 7.02% |
| Return on Capital Employed (ROCE) | 7.61% | 12.30% | 9.91% | 8.94% | 6.77% |
| Return on Invested Capital (ROIC) | 6.65% | 9.56% | 8.39% | 7.28% | 5.08% |
| Return on Tangible Assets | 6.08% | 10.30% | 8.24% | 6.76% | 4.50% |
| Earnings Yield | 3.09% | 3.37% | 3.43% | 3.95% | 3.10% |
| Efficiency Ratios | |||||
| Receivables Turnover | 3.64 | 5.08 | 7.41 | 6.09 | 6.43 |
| Payables Turnover | 15.14 | 17.16 | 29.72 | 18.63 | 51.41 |
| Inventory Turnover | 3.02 | 3.15 | 2.30 | 1.93 | 1.97 |
| Fixed Asset Turnover | 0.72 | 0.75 | 0.63 | 0.47 | 0.41 |
| Asset Turnover | 0.33 | 0.38 | 0.33 | 0.27 | 0.22 |
| Working Capital Turnover Ratio | 0.85 | 1.05 | 0.88 | 0.89 | 1.09 |
| Cash Conversion Cycle | 197.00 | 166.46 | 195.81 | 228.98 | 234.46 |
| Days of Sales Outstanding | 100.32 | 71.91 | 49.25 | 59.92 | 56.72 |
| Days of Inventory Outstanding | 120.79 | 115.82 | 158.84 | 188.65 | 184.84 |
| Days of Payables Outstanding | 24.11 | 21.28 | 12.28 | 19.59 | 7.10 |
| Operating Cycle | 221.11 | 187.73 | 208.09 | 248.57 | 241.56 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 1.71 | 3.91 | 4.07 | 2.69 | 1.49 |
| Free Cash Flow Per Share | 0.31 | 3.40 | 3.85 | 2.47 | 1.10 |
| Dividend Paid and CapEx Coverage Ratio | 0.37 | 1.32 | 1.84 | 1.64 | 1.17 |
| Capital Expenditure Coverage Ratio | 1.22 | 7.74 | 18.32 | 11.91 | 3.82 |
| Operating Cash Flow Coverage Ratio | 0.26 | 1.20 | 0.78 | 0.43 | 0.16 |
| Operating Cash Flow to Sales Ratio | 0.14 | 0.31 | 0.38 | 0.32 | 0.19 |
| Free Cash Flow Yield | 0.43% | 3.27% | 4.96% | 4.55% | 2.22% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 32.41 | 29.63 | 29.17 | 25.33 | 32.21 |
| Price-to-Sales (P/S) Ratio | 5.93 | 8.14 | 7.28 | 6.44 | 6.49 |
| Price-to-Book (P/B) Ratio | 2.66 | 3.79 | 3.19 | 2.37 | 2.26 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 234.23 | 30.58 | 20.18 | 21.98 | 45.14 |
| Price-to-Operating Cash Flow Ratio | 42.44 | 26.63 | 19.08 | 20.13 | 33.33 |
| Price-to-Earnings Growth (PEG) Ratio | -0.90 | 0.93 | 1.20 | 0.65 | -1.59 |
| Enterprise Value Multiple | 18.13 | 18.50 | 17.87 | 14.34 | 18.39 |
| Enterprise Value | 4.90B | 6.71B | 5.03B | 3.42B | 3.26B |
| EV to EBITDA | 18.13 | 18.50 | 17.87 | 14.34 | 18.39 |
| EV to Sales | 5.53 | 7.59 | 7.05 | 6.13 | 6.45 |
| EV to Free Cash Flow | 218.17 | 28.53 | 19.55 | 20.93 | 44.81 |
| EV to Operating Cash Flow | 39.53 | 24.85 | 18.48 | 19.17 | 33.09 |
| Tangible Book Value Per Share | 27.30 | 27.43 | 24.29 | 22.79 | 21.85 |
| Shareholders’ Equity Per Share | 27.32 | 27.45 | 24.32 | 22.83 | 21.90 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.12 | 0.17 | 0.15 | 0.18 | 0.12 |
| Revenue Per Share | 12.23 | 12.78 | 10.66 | 8.42 | 7.64 |
| Net Income Per Share | 2.24 | 3.51 | 2.66 | 2.14 | 1.54 |
| Tax Burden | 0.88 | 0.83 | 0.85 | 0.82 | 0.88 |
| Interest Burden | 0.97 | 0.98 | 0.96 | 0.96 | 0.94 |
| Research & Development to Revenue | 0.11 | 0.07 | 0.07 | 0.09 | 0.13 |
| SG&A to Revenue | 0.40 | 0.39 | 0.36 | 0.33 | 0.30 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.76 | 1.11 | 1.53 | 1.03 | 0.85 |
Currency in TWD
